GlassScriptPhysician profile
Daniel Evan Boykin
NPI 1194380659
$1,566.27
in general payments reported to CMS, 2019-2025
17 companies · $475 in 2025
The $475 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $364 · 2023: $249 · 2024: $479 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,202.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $530.75 | 2022-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $225.42 | 2023-2025 | Vraylar |
| Lilly USA, LLC | $153.15 | 2023-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $138.08 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $127.19 | 2024 | Arexvy |
| Amgen INC. | $75.58 | 2022-2025 | Otezla, Repatha, Prolia |
| Pfizer INC. | $69.20 | 2025 | |
| Exact Sciences Corporation | $34.60 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $33.29 | 2022 | |
| Daiichi Sankyo INC. | $28.24 | 2025 | Injectafer |
| Astellas Pharma US INC | $27.68 | 2023-2024 | Veozah |
| Phathom Pharmaceuticals, INC. | $26.33 | 2024-2025 | Voquezna |
| Corcept Therapeutics | $23.10 | 2025 | Korlym |
| Abbott Laboratories | $22.78 | 2024 | Eterna |
| Xeris Pharmaceuticals, INC. | $20.83 | 2023 | Gvoke Hypopen |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $16.88 | 2025 | Rexulti |
| Dexcom, INC. | $13.17 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Boykin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.